Osimertinib in EGFR Mutation-Positive Advanced NSCLC

被引：25
|
作者：
不详
机构：
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 13期
关键词：
PARAGANGLIOMA;
D O I：
10.1056/NEJMc1801669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1260 / 1261
页数：2
相关论文
共 50 条
  • [1] Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
    Yvette N. Lamb
    Targeted Oncology, 2021, 16 : 687 - 695
  • [2] Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
    Lamb, Yvette N.
    TARGETED ONCOLOGY, 2021, 16 (05) : 687 - 695
  • [3] Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
    Yvette N. Lamb
    Targeted Oncology, 2021, 16 : 869 - 869
  • [4] The relationship between EGFR variant allele frequency and efficacy of osimertinib in EGFR mutation-positive NSCLC
    Katakura, Seigo
    Murakami, Shuji
    Kanako, Shinada
    Ryota, Ushio
    Tetsuro, Kondo
    Terufumi, Kato
    Tomoyuki, Yokose
    Haruhiro, Saito
    ANNALS OF ONCOLOGY, 2022, 33 : S500 - S500
  • [5] Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC (vol 16, pg 687, 2021)
    Lamb, Yvette N.
    TARGETED ONCOLOGY, 2021, 16 (06) : 869 - 869
  • [6] Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R. A.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R.
    Halmos, B.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1045 - S1045
  • [8] Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
    James E. Frampton
    Targeted Oncology, 2022, 17 : 369 - 376
  • [9] Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC
    Frampton, James E.
    TARGETED ONCOLOGY, 2022, 17 (03) : 369 - 376
  • [10] Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
    Imamura, Fumio
    Inoue, Takako
    Kunimasa, Kei
    Kubota, Aki
    Kuhara, Hanako
    Tamiya, Motohiro
    Nishino, Kazumi
    Kimura, Madoka
    Kuno, Kika
    Kawachi, Hayato
    Kumagai, Toru
    LUNG CANCER MANAGEMENT, 2020, 9 (02)
12345